Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

Eli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter ...

One of the key launch points for the modern biotechnology industry was not in the Bay Area or San Diego or Cambridge, ...

Hyderabad, once known as a cradle of culture and history, is now rapidly transforming into a dynamic nerve centre for Global ...

Nuvation has a best-in-class lung cancer drug that could be approved in the US in June. Read why I'm bullish on the stock ...

The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.

Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard therapy for lupus nephritis is more efficacious ...

The Global Capability Centres wave is well underway in India, and the country has an opportunity to become a trusted partner ...

The data, published in JAMA Psychiatry, add to the growing body of evidence supporting the use of GLP-1 receptor agonists for ...

GlobalData’s Revati Tatake discussed key trends in biopharma which are set to have an impact in 2025 and beyond.

Biogen and Eisai have spent much of Leqembi’s launch convincing physicians and patients that it’s safe to treat Alzheimer’s ...

Bayer has acquired full rights to two drugs partnered with Loxo Oncology, on the same day that the biotech was taken over by Eli Lilly in an $ ... is in phase I/II testing as a rescue therapy ...